Niagen Bioscience (NASDAQ:NAGE) Rating Increased to Strong-Buy at Wall Street Zen

Niagen Bioscience (NASDAQ:NAGE) was upgraded by stock analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday.

A number of other research analysts have also recently commented on NAGE. Roth Capital reaffirmed a “buy” rating and set a $23.00 price target (up previously from $10.00) on shares of Niagen Bioscience in a research report on Friday, June 6th. Canaccord Genuity Group boosted their price objective on Niagen Bioscience from $13.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday, June 10th. Finally, HC Wainwright boosted their price objective on Niagen Bioscience from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Monday, August 11th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Niagen Bioscience has a consensus rating of “Buy” and an average price target of $13.42.

Niagen Bioscience Price Performance

Shares of NASDAQ NAGE opened at $10.02 on Friday. Niagen Bioscience has a one year low of $3.10 and a one year high of $14.69. The business’s fifty day moving average price is $11.57 and its 200-day moving average price is $8.43. The stock has a market capitalization of $799.13 million, a PE ratio of 47.72 and a beta of 2.12.

Niagen Bioscience (NASDAQ:NAGE) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.02. Niagen Bioscience had a return on equity of 23.12% and a net margin of 15.24%. The firm had revenue of $31.12 million for the quarter, compared to analysts’ expectations of $28.55 million.

Hedge Funds Weigh In On Niagen Bioscience

A number of institutional investors have recently added to or reduced their stakes in NAGE. JPMorgan Chase & Co. increased its position in shares of Niagen Bioscience by 2.8% during the 4th quarter. JPMorgan Chase & Co. now owns 341,221 shares of the company’s stock valued at $1,810,000 after purchasing an additional 9,305 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Niagen Bioscience by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,154,778 shares of the company’s stock valued at $6,128,000 after purchasing an additional 5,186 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Niagen Bioscience by 42.1% during the 4th quarter. Wells Fargo & Company MN now owns 23,137 shares of the company’s stock valued at $123,000 after purchasing an additional 6,856 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Niagen Bioscience by 68.0% during the 4th quarter. Renaissance Technologies LLC now owns 712,788 shares of the company’s stock valued at $3,781,000 after purchasing an additional 288,588 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Niagen Bioscience during the 4th quarter valued at about $818,000. 15.41% of the stock is currently owned by institutional investors.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.